ERI2 (ERI1 exoribonuclease family member 2) is an exoribonuclease with documented roles in both RNA processing and cancer biology. Functionally, ERI2 possesses 3'-5' RNA exonuclease activity 1 and participates in exonucleolytic trimming to generate the mature 3' end of 5.8S rRNA from the tricistronic rRNA transcript [GO annotations], suggesting involvement in ribosome biogenesis. ERI2 also negatively regulates regulatory ncRNA-mediated heterochromatin formation [GO annotations], indicating roles in gene silencing pathways. In cancer contexts, ERI2 has emerged as a potential oncogenic regulator. It was identified as capable of enhancing MYC promoter activity in a CRISPR-based screening approach combined with database analysis 2, implicating it in proto-oncogene regulation. More clinically, somatic mutations in ERI2 were associated with recurrence in lymph node-negative pancreatic neuroendocrine tumors, appearing among genes with higher mutation burden in recurrent compared to non-recurrent cases 1. Additionally, ERI2 expression patterns showed pleiotropic associations with left ventricular hypertrophy phenotypes in genome-wide studies 3. These findings suggest ERI2 functions in both fundamental RNA metabolism and potentially oncogenic transcriptional regulation, with clinical relevance in tumor recurrence prediction.